These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38416982)

  • 1. Impact of Menopausal Status on Imaging Findings of Patients With Triple-Negative Breast Cancer.
    Avdan Aslan A; Gültekin S; Karakoç E; Tosun SN
    J Breast Imaging; 2022 Jul; 4(4):384-391. PubMed ID: 38416982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of Triple-Negative Breast Cancer: Differences in Clinicopathologic and Ultrasound Features Between Premenopausal and Postmenopausal Patients.
    Zhu K; Wang D; Li Z; Du G; Guo Q; Wu T; Li J
    J Ultrasound Med; 2020 May; 39(5):919-927. PubMed ID: 31737929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.
    Bae MS; Park SY; Song SE; Kim WH; Lee SH; Han W; Park IA; Noh DY; Moon WK
    Eur Radiol; 2015 Feb; 25(2):419-27. PubMed ID: 25224727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer on contrast-enhanced MRI and synthetic MRI: A comparison with non-triple-negative breast carcinoma.
    Matsuda M; Tsuda T; Ebihara R; Toshimori W; Okada K; Takeda S; Okumura A; Shiraishi Y; Suekuni H; Kamei Y; Kurata M; Kitazawa R; Mochizuki T; Kido T
    Eur J Radiol; 2021 Sep; 142():109838. PubMed ID: 34217136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammographic and ultrasonographic features of triple-negative breast cancer compared with non-triple-negative breast cancer.
    Lohitvisate W; Pummee N; Kwankua A
    J Ultrasound; 2023 Mar; 26(1):193-200. PubMed ID: 35976611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
    Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Challenges in Diagnosing Triple-Negative Breast Cancer.
    Schopp JG; Polat DS; Arjmandi F; Hayes JC; Ahn RW; Sullivan K; Sahoo S; Porembka JH
    Radiographics; 2023 Oct; 43(10):e230027. PubMed ID: 37708071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer.
    Zeng Z; Hou CJ; Hu QH; Liu Y; Wang C; Wei R; Fan XM
    Oncotarget; 2017 Oct; 8(45):79670-79679. PubMed ID: 29108347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer.
    Li N; Gong W; Xie Y; Sheng L
    Breast; 2023 Dec; 72():103595. PubMed ID: 37925875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
    Ohashi A; Kataoka M; Iima M; Honda M; Ota R; Urushibata Y; Dominik Nickel M; Toi M; Zackrisson S; Nakamoto Y
    Eur Radiol; 2023 Nov; 33(11):8132-8141. PubMed ID: 37286791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer.
    Nishimura R; Osako T; Okumura Y; Nakano M; Otsuka H; Fujisue M; Arima N
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging Features of Breast Cancer Subtypes on Mammography and Ultrasonography: an Analysis of 479 Patients.
    Pulappadi VP; Dhamija E; Baby A; Mathur S; Pandey S; Gogia A; Deo SVS
    Indian J Surg Oncol; 2022 Dec; 13(4):931-938. PubMed ID: 36687228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
    Youk JH; Son EJ; Chung J; Kim JA; Kim EK
    Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers.
    Boisserie-Lacroix M; Macgrogan G; Debled M; Ferron S; Asad-Syed M; McKelvie-Sebileau P; Mathoulin-Pélissier S; Brouste V; Hurtevent-Labrot G
    Oncologist; 2013; 18(7):802-11. PubMed ID: 23821326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographic and clinicopathological features of triple-negative breast cancer.
    Gao B; Zhang H; Zhang SD; Cheng XY; Zheng SM; Sun YH; Zhang DW; Jiang Y; Tian JW
    Br J Radiol; 2014 Jul; 87(1039):20130496. PubMed ID: 24734934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
    Wijesinghe HD; Fernando J; Senarath U; Wijesinghe GK; S Lokuhetty MD
    Indian J Pathol Microbiol; 2020; 63(3):388-396. PubMed ID: 32769327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
    Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
    Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.